Dipeptidylpeptidase (DPP)-4 inhibitor therapy increases circulating levels of anti-inflammatory soluble frizzle receptor protein (sFRP)-5 which is decreased in severe COVID-19 disease

Obesity and type 2 diabetes (T2D) show an increased risk for a severe COVID-19 disease. Treatment with DPP4 inhibitor (DPP4i) results in reduced mortality and better clinical outcome. Here, we aimed to identify potential mechanisms for the observed DPP4i effect in COVID-19. Comparing T2D subjects wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Brandes, Juliane, Zobel, Isabelle, Rohmann, Nathalie, Schlicht, Kristina, Geisler, Corinna, Hartmann, Katharina, Türk, Kathrin, von Schönfels, Witigo, Beckmann, Jan, Tran, Florian, Laudes, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437412/
https://www.ncbi.nlm.nih.gov/pubmed/36056109
http://dx.doi.org/10.1038/s41598-022-18354-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437412/
https://www.ncbi.nlm.nih.gov/pubmed/36056109
http://dx.doi.org/10.1038/s41598-022-18354-x

Ejemplares similares